Patients capable of performing mobile hyperacuity home-monitoring benefit in terms of visual acuity and discontinue treatment less often than patients not using home monitoring bmjopen.bmj.com/content/11/1…#ophthalmology#retina
We are on the move – not only in our projects, but literally. As of March 1, you will find medignition, @AlleyeApp , Augenmobil and @CuraData at Engelstrasse. Enjoy the first sneak peek and stay tuned to see what the indoors look like, once we have unpacked!
A new study by a group of Swiss, British and US American researchers investigates the visual outcomes and treatment adherence of patients with macular pathology using a mobile hyperacuity home monitoring app. Read the results here: bmjopen.bmj.com/content/11/1…
We learnt a lot from the interesting cases and faculty discussions during last nights inaugural EURETINA Case Club with the #retina fellows from @Moorfields Eye Hospital. If you missed it why not check out the replay here: ow.ly/HTO550GLA1n#ophthalmology@YoungRetina
The eyes are a window into the soul - and a lens into disease. Brilliant talk by the amazing @sktywagner on AI and the eye to spot dementia.
youtube.com/watch?v=2oxsQJm3…
We are delighted to announce our 2021 Power List of the Top 100 Women in Ophthalmology, celebrating the impact our nominees have had on ophthalmic clinical practice, research, education, and industry.
Click below to see who made this year's list!
bit.ly/3rBkD6r
The share of the population aged 65 years increased from 6% in 1990 to 9% in 2019. It is expected that this proportion rises to 16% in 2050.
Source: @OurWorldInData
DECIDE-AI encourages early small-scale evaluation of #AI prior to clinical trials. These stepping stone studies are an opportunity to test #safety, human factors & user trust before launching into big clinical trials.
go.nature.com/3oDe5Tr
Grab your tickets now at lnkd.in/dSZ-SFr
Siegfried Wagner, an ophthalmologist at Moorfields Eye Hospital, has been working on this #AlzEye research project, which attempts to use the eye as a window to detect signals about the health of other organs.
@sktywagner
Moorfields' 12-year dataset of anti-VEGF in nAMD deidentified and made open-source. Survival analysis shows that patients were likely to experience positive visual outcome within 2 years, which was sustained for another year ja.ma/3fd42Br@EyeCharity
Our new paper in @JAMAOphth from the @pearsekeane team
We propose time-event analyses as the standard for visual outcome analysis in retrospective, real-world ophthalmology studies.
Using these methods on (n=7802) nAMD patients @Moorfields produced long-term prognostic insights
Moorfields' 12-year dataset of anti-VEGF in nAMD deidentified and made open-source. Survival analysis shows that patients were likely to experience positive visual outcome within 2 years, which was sustained for another year ja.ma/3fd42Br@EyeCharity
Out now! our paper on findings from a global survey of 214 retina experts on the implementation of digital health in retina care during the #covid19 pandemic, led by the brilliant @FaesLiv, on behalf of the International Retinal Collaborative @allerganeye bjo.bmj.com/content/early/20…